Future of Biden's plan for Medicaid to cover obesity drugs

Biden Says Medicare, Medicaid Should Cover Obesity Drugs—What Could That Mean for Access?
The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity medications. But it's not clear if the proposed change will go into effect.
Biden proposes expanding obesity drug coverage under Medicare and Medicaid
The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans with Medicare and Medicaid.
Biden proposes anti-obesity drug rule
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden proposes Medicaid, Medicare cover obesity drugsA proposed rule from the Biden administration
Opinion
White House rule would expand coverage of anti-obesity drugs
It’s unclear whether incoming President Donald J. Trump will support outgoing President Joe Biden’s plan to insure the weight loss drugs.
CMS’ obesity drug coverage implications for nursing home patients
A new rule proposed by CMS presents alterations to the Medicare program, including expanded coverage for anti-obesity medications.
Biden administration adds weight-loss drugs to Medicare
While recent advances in medicine have created prescription anti-obesity GLP-1 medications — like Ozempic, Wegovy, and Mounjaro — accessibility to these drugs is limited. The average prescription costs $1,
Biden's plan to cover anti-obesity drugs could cost $140 billion
President Joe Biden's plan to authorize Medicare and Medicaid cover anti-obesity medications starting in 2026 would $140 billion over the next decade.
The future of Biden's plan for Medicaid to cover obesity drugs
Drugs used for weight loss like Wegovy and Zepbound could be covered by Medicare or Medicaid under a new proposal from the Biden administration.
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
BioPharma Dive3d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Biohaven's Revenue Path: SCA And Obesity Therapies
Biohaven's pipeline includes Troriluzole for SCA, BHV-2100 for migraines, and Taldefgrobep Alfa for SMA. See why BHVN stock ...
Novo Nordisk launches obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...
Cheap Ozempic? How millions of Americans with obesity may get access to costly weight-loss drugs
Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...
New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...